Compare ARK Fintech Innovation ETF (ARKF) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Novo Nordisk A/S — how do they compare? ARK Fintech Innovation ETF trades at $43, while Novo Nordisk A/S trades at $45.77 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while ARK Fintech Innovation ETF pays none. Which is the better fit depends on your goals.
| ARKF | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $63.98 |
52-Week Low | $36.14 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.54, up 1.48% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has underperformed the S&P 500, down 23% since July 2025, and faces elevated volatility. Recent news highlights its fintech and crypto exposure amid market consolidation, with a Hold rating due to fair valuation concerns.
Outlook remains cautious; high P/E of 33x and PEG of 2.0x suggest overvaluation risks, while sector consolidation offers potential recovery if market sentiment improves. Key risks include sustained underperformance and portfolio volatility, requiring careful monitoring of fintech sector trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
